Abstract
Triple-negative breast cancer (TNBC) is associated with metabolic heterogeneity and poor prognosis with limited treatment options. New treatment paradigms for TNBC remains an unmet need. Thus, therapeutics that target metabolism are particularly attractive approaches. We previously designed organometallic Au(III) compounds capable of modulating mitochondrial respiration by ligand tuning with high anticancer potency in vitro and in vivo. Here, we show that an efficacious Au(III) dithiocarbamate (AuDTC) compound induce mitochondrial dysfunction and oxidative damage in cancer cells. Efficacy of AuDTC in TNBC mouse models harboring mitochondrial oxidative phosphorylation (OXPHOS) dependence and metabolic heterogeneity establishes its therapeutic potential following systemic delivery. This provides evidence that AuDTC is an effective modulator of mitochondrial respiration worthy of clinical development in the context of TNBC. One sentence summary: Metabolic-targeting of triple-negative breast cancer by gold anticancer agent may provide efficacious therapy.
Original language | English |
---|---|
Article number | 116010 |
Journal | Biomedicine and Pharmacotherapy |
Volume | 170 |
DOIs | |
State | Published - Jan 2024 |
Bibliographical note
Publisher Copyright:© 2023 The Authors
Keywords
- Gold
- Mitochondria
- OXPHOS
- Triple negative breast cancer
ASJC Scopus subject areas
- Pharmacology